Your shopping cart is currently empty

Flonoltinib maleate is an orally effective dual JAK2/FLT3 inhibitor, with IC50 values of 0.7 nM for JAK2, 4 nM for FLT3, 26 nM for JAK1, and 39 nM for JAK3. Known as JAK2/FLT3-IN-1, it exhibits anticancer activity.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | Flonoltinib maleate is an orally effective dual JAK2/FLT3 inhibitor, with IC50 values of 0.7 nM for JAK2, 4 nM for FLT3, 26 nM for JAK1, and 39 nM for JAK3. Known as JAK2/FLT3-IN-1, it exhibits anticancer activity. |
| Targets&IC50 | JAK2:0.7 nM, JAK3:39 nM, JAK1:26 nM |
| In vitro | Flonoltinib maleate (0.008-1 μM; for 2 hours) dose-dependently downregulates p-FLT3. Additionally, Flonoltinib maleate (5-100 nM; for 2 hours) exhibits a dose-dependent induction of apoptosis in MV4-11 cells. At a concentration of 100 nM, Flonoltinib maleate significantly induces cell cycle arrest, with an 85% increase in the G1/G0 phase in MV4-11 cells. |
| In vivo | Flonoltinib maleate, administered orally at doses of 30 and 60 mg/kg/day over a continuous period of 14 days, demonstrated significant antitumor activity. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.